Partial
Partially Aligned
Patient Risk:
Medium
Summary
Some safety-related claims (addiction/abuse/misuse and life-threatening respiratory depression) align with provided FDA label sections, and the general indication for opioid analgesic use in acute severe pain with inadequate alternatives is directionally consistent. However, many non-label claims about pricing/insurance/generics/patents are unsupported, several adverse effect claims (nausea, vomiting, constipation, dizziness, drowsiness) are unsupported by provided label excerpts, and at least one formulation claim (extended-release availability) is not supported by the provided dosage forms excerpt.
Category Scores
Accurate Statements
Nucynta carries risks including the potential for abuse.
Supported by Warnings and Precautions 5.1 (Addiction, Abuse, and Misuse), which states NUCYNTA exposes users to risks of addiction, abuse, and misuse.
Nucynta carries risks including addiction.
Supported by Warnings and Precautions 5.1 (Addiction, Abuse, and Misuse).
Nucynta carries risks including life-threatening respiratory depression.
Supported by Warnings and Precautions 5.2 (Life-Threatening Respiratory Depression), stating serious, life-threatening, or fatal respiratory depression has been reported with opioids including NUCYNTA.
Unsupported Statements
The retail price of Nucynta (tapentadol) varies depending on dosage, quantity, and pharmacy.
No retail pricing information is present in the provided FDA label sections.
A prescription for 30 tablets of Nucynta 50 mg can range from approximately $300 to over $400.
Specific dollar pricing ranges are not included in the provided FDA label sections.
Prices may differ for Nucynta ER (extended-release) formulations.
No pricing statements or ER pricing comparisons are present in the provided FDA label sections.
Coverage for Nucynta by insurance plans can vary.
Insurance coverage/payment statements are not part of the provided FDA label sections.
Many insurance providers may cover a portion of the cost of Nucynta.
Insurance reimbursement statements are not included in the provided FDA label sections.
Whether Nucynta is considered a preferred medication can affect insurance coverage.
Formulary/preferred medication statements are not present in the provided FDA label sections.
A prior authorization may be required for insurance coverage of Nucynta.
Prior authorization guidance is not included in the provided FDA label sections.
As of late 2023, generic versions of Nucynta have become available.
Generic availability timing is not included in the provided FDA label sections.
The introduction of generics can significantly impact pricing, often leading to lower costs compared to the brand-name drug.
Economic/predictive statements about pricing impacts are not included in the provided FDA label sections.
Nucynta is available in both immediate-release and extended-release formulations.
The provided Dosage Forms and Strengths excerpt lists tablets only (50 mg, 75 mg, 100 mg) and does not support an extended-release formulation claim.
The patent protection for Nucynta has largely expired.
Patent status is not provided in the supplied FDA label sections.
Nucynta should be used with caution and only as prescribed by a healthcare professional.
The exact phrasing is not directly supported by the provided excerpts; the provided sections emphasize proper dosing/titration and include patient counseling to read a Medication Guide, but do not clearly confirm the specific 'with caution' and 'only as prescribed' wording from the excerpts.
Other side effects of Nucynta can include nausea.
The provided FDA label excerpts do not support nausea as an adverse reaction.
Other side effects of Nucynta can include vomiting.
The provided FDA label excerpts do not support vomiting as an adverse reaction.
Other side effects of Nucynta can include constipation.
The provided FDA label excerpts do not support constipation as an adverse reaction.
Other side effects of Nucynta can include dizziness.
The provided FDA label excerpts do not support dizziness as an adverse reaction.
Other side effects of Nucynta can include drowsiness.
The provided FDA label excerpts do not support drowsiness as an adverse reaction.
Contradictions
Important Omissions
No verified inclusion of key boxed-warning elements and other boxed warning topics beyond the limited safety claims provided (e.g., neonatal opioid withdrawal syndrome; interactions with benzodiazepines/other CNS depressants; guidance on patient selection/monitoring).
Importance:
Moderate
No verified adverse reaction statements supported by the provided Adverse Reactions section beyond listing that adverse reactions are discussed elsewhere; symptom-specific adverse effects claimed (nausea, vomiting, constipation, dizziness, drowsiness) were not label-cited.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Safety-related claims about abuse/addiction and life-threatening respiratory depression align with the provided label sections, but multiple unsupported adverse effect claims and several unsupported non-label topics (pricing/insurance/generics/patent status) could mislead users about safety/treatment context. The omission of additional boxed-warning elements in the evaluated content limits label completeness.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Many statements are not supported by the provided FDA labeling (especially pricing/insurance/generics/patent status and symptom-specific adverse effects). Extended-release formulation availability is also not supported by the provided dosage forms excerpt.
Suggested Improvement
Remove or relabel non-label economic/insurance/generic/patent claims; only state formulation/availability details that are explicitly supported by the provided label excerpts; avoid listing specific adverse effects (nausea/vomiting/constipation/dizziness/drowsiness) unless directly supported by cited label adverse reaction sections; include additional boxed-warning topics with proper label support where relevant.